1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Wesana Health Holdings Inc.
  6. News
  7. Summary
    WESA   CA95081C1059

WESANA HEALTH HOLDINGS INC.

(WESA)
  Report
Delayed CANADIAN NATIONAL STOCK EXCHANGE  -  01:18 2022-06-30 pm EDT
0.1850 CAD   +2.78%
06/08WESANA HEALTH CEO DANIEL CARCILLO TO KEYNOTE CHARLES RIVER SYMPOSIUM : Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairman
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Wesana Health Holdings Outlines Accelerated Drug Development Pathway

05/10/2022 | 07:30am EDT

Wesana Health Holdings Inc. announced that following the completion of a successful Pre-IND meeting with the United States Food and Drug Administration (“FDA”), the company is expanding its lead indication for SANA-013 to Major Depressive Disorder (“MDD”) and exploring other complementary orphan indications. Consistent with the positive feedback received from FDA, Wesana will accelerate the development of SANA-013 by initiating a Phase 1b/2a human study for MDD in the first half of 2023. In contrast to the prior development pathway for SANA-013 with TBI associated depression as the lead indication, the revised development pathway would allow the Company to bypass the healthy patient population study and research an MDD affected patient population directly as part of a Phase 1b/2a study. Wesana’s SANA-013 is designed to deliver a novel depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a non-hallucinogenic dose of psilocybin combined with cannabidiol (CBD). The low, non-hallucinogenic dose of psilocybin in combination with CBD is being developed for MDD and other indications so that affected people can benefit from a chronic, at-home use proposition.


© S&P Capital IQ 2022
All news about WESANA HEALTH HOLDINGS INC.
06/08WESANA HEALTH CEO DANIEL CARCILLO TO : Re-Imagining Substance Abuse, Addiction, and Mental..
AQ
05/31Wesana Announces First Quarter 2022 Financial Results
AQ
05/31Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairm..
CI
05/30Wesana Health Holdings Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/10Wesana Health Outlines Accelerated Drug Development Pathway
AQ
05/10Wesana Health Holdings Outlines Accelerated Drug Development Pathway
CI
05/05Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its..
AQ
05/05Wesana Health Holdings Announces Review of Strategic Alternatives of its Clinics and Ot..
CI
05/02Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highligh..
AQ
05/02Wesana Health Holdings Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
More news
Financials (USD)
Sales 2022 1,56 M - -
Net income 2022 -21,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,29x
Yield 2022 -
Capitalization 2,92 M 2,91 M -
Capi. / Sales 2022 1,87x
Capi. / Sales 2023 1,07x
Nbr of Employees -
Free-Float 99,1%
Chart WESANA HEALTH HOLDINGS INC.
Duration : Period :
Wesana Health Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,14 $
Average target price 3,09 $
Spread / Average Target 2 052%
EPS Revisions
Managers and Directors
Daniel Carcillo Chief Executive Officer & Director
Zed Wang Chief Financial Officer & Secretary
Chad Bronstein Executive Chairman
Mark Wingertzahn Chief Scientific Officer
Mitchell Kahn Director
Sector and Competitors
1st jan.Capi. (M$)
WESANA HEALTH HOLDINGS INC.-87.06%3
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.60%19 031